To understand the effectiveness and implementation of the SCP-PHR, we will conduct a hybrid type 1 effectiveness-implementation trial consisting of the following components: (A) a randomized clinical effectiveness trial, and (B) a mixed methods implementation study.
1 Primary · 2 Secondary · Reporting Duration: 12 months
Active Control
Experimental Treatment
250 Total Participants · 2 Treatment Groups
Primary Treatment: Intervention · No Placebo Group · N/A
Age 18 - 99 · All Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: